Hepatitis B
Conditions
Keywords
Adjuvanted hepatitis B vaccine, Hepatitis B, Recombinant hepatitis B vaccine
Brief summary
The purpose of the present study is to evaluate the immunogenicity and safety of three consecutive production lots of the novel adjuvanted HBV vaccine. The safety of the candidate vaccine will be assessed using Engerix™-B as control.
Detailed description
Double-blind for the identity of the consistency lots, single-blind for the control group/study vaccine identity. At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham
Interventions
BIOLOGICALHBV-MPL vaccine 208129
3 consecutive lots; 3-dose intramuscular injection
BIOLOGICALEngerix™-B
3-dose intramuscular injection
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
15 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* A male or female between, and including, 15 and 50 years of age at the time of the first vaccination. * Written informed consent obtained from the subject/ from the parents or guardians of the subject where applicable * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * If the subject is female, she must be of non-childbearing potential, or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
Exclusion criteria
* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Planned administration/Administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s). * Previous vaccination against hepatitis B * History of non-response to previous hepatitis B vaccination * Known exposure to hepatitis B within the previous 6 weeks * History of hepatitis B infection * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * A family history of congenital or hereditary immunodeficiency. * Suspected or confirmed multiple sclerosis in the subject (applicable to Centre 5/France only) * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Acute disease at the time of enrolment. * Hepatomegaly, right upper quadrant abdominal pain or tenderness. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * Pregnant or lactating female
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Anti-HBs antibody concentrations | At month 3 |
Secondary
| Measure | Time frame |
|---|---|
| Anti-HBs antibody concentrations | At M1, M2, M3 |
| Anti-RF1 antibody titres in a subset of 50 subjects per group | At months 0 and 3 |
| Occurrence, intensity and relationship to vaccination of solicited local and general signs and symptoms | During a 4-day follow-up after vaccination |
| Occurrence, intensity and relationship to vaccination of unsolicited symptoms | Within 30 days after each vaccination |
| Occurrence, intensity and relationship to vaccination of serious adverse events | During the study period |
Outcome results
None listed